Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000728599 | SCV000241881 | likely benign | not provided | 2020-09-25 | criteria provided, single submitter | clinical testing | |
Genetic Services Laboratory, |
RCV000188271 | SCV000248279 | uncertain significance | not specified | 2014-07-18 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV000515422 | SCV000611415 | uncertain significance | Pitt-Hopkins-like syndrome 2; Chromosome 2p16.3 deletion syndrome | 2017-05-23 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000706193 | SCV000835231 | likely benign | Pitt-Hopkins-like syndrome 2 | 2025-02-04 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002317133 | SCV000851423 | uncertain significance | Inborn genetic diseases | 2021-10-15 | criteria provided, single submitter | clinical testing | Unlikely to be causative of NRXN1-related neurodevelopmental disorder (AD) Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Eurofins Ntd Llc |
RCV000728599 | SCV000856192 | uncertain significance | not provided | 2017-08-23 | criteria provided, single submitter | clinical testing | |
Mayo Clinic Laboratories, |
RCV000728599 | SCV002541829 | uncertain significance | not provided | 2021-07-21 | criteria provided, single submitter | clinical testing |